Dopaminergic sensitivity and prediction of antidepressant response

Abstract

This study was designed to examine neuroendocrine predictors of antidepressant response to the selective serotonin reuptake inhibitor (SSRI) paroxetine. We assessed the prognostic utility of the apomorphine stimulation test by examining the relationship between pretreatment change in growth hormone (GH) following apomorphine and acute response to paroxetine treatment. We hypothesized that those subjects with most marked pretreatment dopaminergic supersensitivity, as manifested by greatest change in GH, would be most likely to show an early antidepressant response and would also be more likely to develop manic or hypomanic symptoms on paroxetine. Contrary to our hypothesis, greater dopamine postsynaptic sensitivity was associated with greater resistance to paroxetine treatment. In our sample of 13 subjects with a major depressive episode, pretreatment GH response to apomorphine per unit weight was inversely correlated with change in Hamilton depression rating scale following 6 weeks of paroxetine. Within the group of subjects who showed mood elevation on paroxetine, there was a trend towards greater GH response being associated with slower antidepressant response. With regard to the development of manic or hypomanic symptoms on paroxetine, change in GH per unit weight not did distinguish the two subjects who subsequently developed paroxetine-induced hypomania from other subjects. The seven subjects with previous antidepressant-induced hypomania did not differ from the other subjects in change in GH response per unit weight. The finding that subjects who had low dopamine receptor responsivity pretreatment were more likely to have an antidepressant response with paroxetine is consistent with recent suggestions that the therapeutic effect of SSRIs may be mediated through increased dopamine receptor sensitivity in the mesolimbic system. Further work assessing pretreatment and post-treatment GH response to apomorphine will help to test the hypothesis that low dopamine receptor responsivity predicts antidepressant response to SSRIs.

Keywords

antidepressant-induced mania apomorphine dopaminergic supersensitivity paroxetine SSRIs

Get full access to this article

View all access options for this article.

References

Ansseau M , von Frenckell R , Cerfontaine J L , Papart P , Franck G , Timsit-Berthier M , Geenen V , Legros J J (1988) Blunted response of growth hormone to clonidine and apomorphine in endogenous depression. Br J Psychiatry 153: 65–71

Bauer M , Zaninelli R , Muller-Oerlinghausen B , Meister W (1999) Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study. J Clin Psychopharmacol 19: 164–171

Benazzi F (1997) Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice. J Affect Disord 46: 73–77

Bottlender R , Rudolf D , Strauss A , Moller H-J (1998) Antidepressant-associated maniform states in acute treatment of patients with bipolar-I depression. Eur Arch Psychiatry Clin Neurosci 248: 296–300

Bouckoms A , Mangini L (1993) Pergolide: an antidepressant adjuvant for mood disorders? Psychopharmacol Bull 29: 207–211

D'haenen H A H , Bossuyt A (1994) Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry 35: 128–132

D'haenen H A H , Steenssens D , Bossuyt A (1999) Successful Antidepressant treatment with SSRIs is associated with an increased D2 binding. Int J Neuropsychopharmacol 2: S14-S14

Diehl D J , Gershon S (1992) The role of dopamine in mood disorders. Compr Psychiatry 33: 115–120

Diler R S , Avci A (1999) SSRI-induced mania in obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 38: 6–7

10.

Ebert D , Feistel H , Kaschka W , Barocka A , Pirner A (1994) Single photon computerized tomography assessment of cerebral dopamine D2 receptor blockade before and after sleep deprivation – preliminary results. Biol Psychiatry 35: 880–885

11.

Ebert D , Feistel H , Loew T , Pirner A (1996) Dopamine and depression – striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Psychopharmacology 126: 91–94

12.

Gessa G L (1996) Dysthymia and depressive disorders: dopamine hypothesis. Eur Psychiatry 11: 123S–127S

13.

Inoue T , Tsuchiya K , Miura J , Sakakibara S , Denda K , Kasahara T , Koyama T (1996) Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol Psychiatry 40: 151–153

14.

Joyce P R (1994) Predictors for treatment response and treatment selection. Curr Opin Psychiatry 7: 26–29

15.

Lal S (1988) Apomorphine in the evaluation of dopaminergic function in man. Prog Neuropsychopharmacol Biol Psychiatry 12: 117–164

16.

Maj J , Wedzony K , Klimek V (1987) Desipramine given repeatedly enhances behavioural effects of dopamine and D-amphetamine injected into the nucleus accumbens. Eur J Pharmacol 140: 179–185

17.

Maj J , Rogoz Z , Dziedzicka-Wasylewska M , Margas W (1999) Venlafaxine, a new antidepressant given repeatedly, affects brain dopamine D2 and D3 receptors. Int J Neuropsychopharmacol 2: S3-S3

18.

Meakin C J , Brockington I F , Lynch S , Jones S R (1995) Dopamine supersensitivity and hormonal status in puerperal psychosis. Br J Psychiatry 166: 73–79

19.

Mir S (1998) Antidepressant-induced switching in bipolar affective disorder. In Taylor D , Paton C (eds), Case studies in psychopharmacology: the use of drugs in psychiatry. London: Martin Dunitz, London

20.

Murphy D , Mitchell P B , Potter W Z (1995) Novel pharmacological approaches to the treatment of depression. In Bloom F E , Kupfer D J (eds), Psychopharmacology: the fourth generation of progress. New York: Raven Press, New York

21.

Muscat R , Sampson D , Willner P (1990) Dopaminergic mechanism of imipramine action in an animal model of depression. Biol Psychiatry 28: 223–230

22.

Peet M (1994) Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants. Br J Psychiatry 164: 549–550

23.

Pitchot W , Hansenne M , Moreno AG , Ansseau M (1996) Growth hormone response to apomorphine in obsessive-compulsive disorder. J Psychiatr Neurosci 21: 343–345

24.

Roberts D C S , Koob G F , Klonoff P , Fibiger H C . Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens. Pharmacol Biochem Behav 1980 12: 781–787

25.

Scappa S , Teverbaugh P , Ananth J (1993) Episodic tardive dyskinesia and parkinsonism in bipolar disorder patients. Can J Psychiatry 38: 633–634

26.

Simon B , Appel J B (1997) Dopaminergic and serotonergic properties of fluoxetine. Prog Neuropsychopharmacol Biol Psychiatry 21: 169–181

27.

Stoll A L , Pillay S S , Diamond L , Workum S B , Cole J O (1996) Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry 57: 72–76

28.

Tanda G , Frau R , Di Chiara G (1995) Local 5HT3 receptors mediate fluoxetine but not desipramine-induced increase of extracellular dopamine in the prefrontal cortex. Psychopharmacology 119: 15–19

29.

Tulandi T , Lal S , Guyda H (1987) Effect of estrogen on the growth hormone response to the alpha-adrenegic agonist clonidine in women with menopausal flushing. J Clin Endocrinol Metabol 65: 6–10

30.

Willner P , Sampson D , Phillips G , Muscat R (1990) Dopaminergic and non-dopaminergic mechanisms of antidepressant drug action in realistic animal models. In Gessa G L , Serra G (eds), Dopamine and mental depression. Oxford: Pergamon Press, Oxford

31.

Willner P (1995) Dopaminergic mechanisms in depression and mania. In Bloom F E , Kupfer, D J (eds), Psychopharmacology: the fourth generation of progress. New York: Raven Press, New York